Updates from Syncona and our portfolio companies
A new Syncona company exploiting the wound healing ability of macrophages to stimulate organ repair following severe injury as a result of chronic disease. Syncona Partners, Ed Hodgkin and Gonzalo Garcia, discuss founding this new company.
Watch Syncona Partner, Dominic Schmidt discuss how we sourced and founded our new kidney gene therapy company, Purespring
Iraj Ali, Charlie Swanton and Karl Peggs discuss the dosing of the first melanoma patient with a cell therapy to specifically target all cancer cells. This marks a significant milestone for Achilles, delivering the first precision TIL therapy
An animation explaining what gene therapy is, how it has evolved over 50 years and the goal of providing a long-term cure for patients who receive treatment.
Freeline Data Update at EAHAD conference 7 Feb 2020 – watch our video overview
Syncona’s Chief Investment Officer, Chris Hollowood and Syncona Partner, Dominic Schmidt explain how Syncona has built a globally leading platform of unpartnered gene therapy assets.